AQST Aquestive Therapeutics

Aquestive Therapeutics to Announce Third Quarter Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET

Aquestive Therapeutics to Announce Third Quarter Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET
EN
14/10/2020

Underlying

AQSTAquestive Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aquestive Therapeutics

 PRESS RELEASE
Free
AQST Aquestive Thera...

Aquestive Therapeutics Announces that FDA Will Not Require an Advisory...

Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm™ NDA remains on track for FDA PDUFA goal date of January 31, 2026Commercial planning continues enabling rapid launch following approval WARREN, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that the U.S. Food and Drug Admin...

September 4, 2025 1 EN
 PRESS RELEASE
Free
AQST Aquestive Thera...

Aquestive Therapeutics to Participate in Upcoming September Investor C...

Aquestive Therapeutics to Participate in Upcoming September Investor Conferences WARREN, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in three upcoming investor conferences in September 2025 as follows: Cantor Healthcare Conference: fireside chat at 8:00 am ET on Thursday, September 4th and available to host inves...

August 26, 2025 1 EN
 PRESS RELEASE
Free
AQST Aquestive Thera...

Aquestive Therapeutics Announces Pricing of $85 Million Underwritten O...

Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the pricing of an underwritten offering of 21,250,000 shares of its common stock at an offering price of $4.00 per share. The gross proceeds of the offering to Aquestive, before deducting the underwriting discou...

August 14, 2025 1 EN
 PRESS RELEASE
Free
AQST Aquestive Thera...

Aquestive Therapeutics Announces $75M Strategic Funding Agreement with...

Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film Anaphylm launch funding of $75 million committed by RTW, subject to FDA approval of Anaphylm and other conditions Strategic financing will further strengthen the Company’s balance sheet in advance of potential commercialization of Anaphylm for the emergency treatment of allergic reactions, including anaphylaxis WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharm...

August 14, 2025 1 EN
 PRESS RELEASE
Free
AQST Aquestive Thera...

Aquestive Therapeutics Reports Second Quarter 2025 Financial Results a...

Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update FDA accepts NDA submission for Anaphylm™; PDUFA date set for January 31, 2026Planning continues for a Q1 2026 U.S. launch of Anaphylm, if approved by the FDACompany accelerates Anaphylm global expansion strategy to Canada and the EUCompany to host investor call on August 12, 2025, at 8:00am ET WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement ...

August 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch